(MedPage Today) — Immunotherapy-based combinations have rapidly become the dominant first-line treatment for advanced hepatocellular carcinoma (HCC), but real-world outcomes remain heavily constrained by liver function and comorbidity burden…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/119226
Author :
Publish date : 2025-12-30 21:37:00
Copyright for syndicated content belongs to the linked Source.
